- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Apheresis Market by Product (Device, Disposable), Procedure [Donor, Therapeutic (Neurological, Blood)], Application (Plasmapheresis, Plateletpheresis), Technology (Centrifugation, Membrane Separation), End User (Clinic) - Global Forecast to 2031
USD 4.41 BN
MARKET SIZE, 2031
CAGR 7.9%
(2026-2031)
500
REPORT PAGES
380
MARKET TABLES
APHERESIS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, at a CAGR of 7.9% during the forecast period. The market was valued at USD 2.81 billion in 2025. The growth of the apheresis market is driven by the rising number of cases of chronic diseases, autoimmune diseases, hematologic conditions, and neurological disorders, as well as an increased need for plasma products. The increasing use of advanced technologies in blood separation, the establishment of plasma centers, favorable government initiatives for blood donation programs, and technological advances in apheresis devices are contributing to market growth.
KEY TAKEAWAYS
-
BY REGION
The Asia Pacific is anticipated to have the highest CAGR during the forecast period.
-
BY PRODUCT
Apheresis disposables are expected to dominate the offering segment, with an 83.4% share in 2025.
-
BY TYPE
Donor apheresis is expected to register the highest CAGR of 58.2% during the forecast period.
-
BY TECHNOLOGY
Centrifugation is projected to hold 79.8% of the market during the forecast period.
-
COMPETITIVE LANDSCAPE (KEY PLAYERS)
Major market players have adopted both organic and inorganic strategies, including partnerships and investments. For instance, Terumo Corporation (Japan), Fresenius SE & Co. KGaA (Germany), and Haemonetics Corporation (US) have entered into a number of agreements and partnerships to cater to the growing demand for apheresis across innovative applications.
-
COMPETITIVE LANDSCAPE (STARTUPS/SMES)
Macopharma SA (France), Infomed SA (Switzerland), Therakos LLC (UK), and Haier Biomedical (China), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global apheresis market is experiencing steady growth, driven by rising rates of chronic diseases and autoimmune and hematological disorders, as well as rising demand for plasma-based treatments worldwide. New deals and developments, including strategic partnerships between healthcare service providers and medical equipment makers, investments in recycling technologies, and innovations in cell collection for cellular and genetic treatments, are reshaping the industry landscape.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on consumers' business emerges from customer trends or disruptions. Blood collection centers, hospitals & transfusion centers, and other end users are clients of apheresis manufacturers, and patients requiring therapeutic apheresis and donors participating in blood component collection are clients of apheresis systems. Shifts, which are changing trends or disruptions, will impact the revenues of end users. The revenue impact on end users will affect the revenue of Blood collection centers, hospitals & transfusion centers, and other end users, which will further affect the revenues of apheresis manufacturers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Rising prevalence of autoimmune and neurological disorders
-
Increasing Utilization of Plasma-Derived Biologics by Biopharmaceutical Companies
RESTRAINTS
Impact
Level
-
High Procedural and Operational Costs
-
Limited Adoption of Apheresis Donation Procedures in Emerging Economies
OPPORTUNITIES
Impact
Level
-
Adoption of Apheresis Procedures in Leukemia and Pediatric Patients
-
Growing Investments in Emerging Markets by Governments and Key Industry Players
CHALLENGES
Impact
Level
-
Risk of Procedure-Related Adverse Events and Donor Safety Concerns
-
Risk of Transfusion-Transmitted Infections and Inadequate Blood Screening Infrastructure in Emerging Countries
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The rising prevalence of autoimmune and neurological disorders is a key driver of the apheresis market. According to the National Institute of Allergy and Infectious Diseases (NIAID), an estimated 8% of the U.S. population had an autoimmune disease in 2025, including more than 80 different disorders, which can be chronic and may usually require long-term treatment, further increasing the demand for apheresis.
Despite their advantages, apheresis devices and disposables come with high production and processing costs. These costs are further escalated by complex manufacturing requirements, maintenance services, and lengthy regulation processes. Furthermore, inadequate reimbursement coverage in developing economies may constrain patient acceptance.
Increased adoption of apheresis procedures among leukemia and pediatric patients is driving several growth prospects for the apheresis market. Therapeutic apheresis is increasingly used in the management of leukemias to reduce leukemic white blood cell counts in a short time. The use of therapeutic apheresis procedures in pediatric patients is also gradually increasing due to expanding applications in pediatric hematological disorders, autoimmune diseases, neurological disorders, and stem cell transplantation procedures.
Procedure-induced adverse effects and safety concerns with regard to the donor represent a significant issue facing the apheresis industry. Possible procedure-induced adverse effects include hypotension, citrate toxicity, allergic reaction, problems with accessing the blood vessels, electrolyte disturbances, and even infections that can occur during extended or repeated procedures. Plasma donors who receive plasma frequently may suffer from fatigue, hypocalcemia, bruises, and lower number of blood components.
APHERESIS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Manufactures donor blood collection and therapeutic apheresis equipment, such as Spectra Optia and Trima Accel, which facilitate the collection of plasma, platelets, and red blood cells in hospitals and blood donation centers. | Ensures greater efficiency, safety, automation, and quality in the collection process of blood components, as well as provides an opportunity to collect high-quality plasma during shorter procedure times. |
|
|
Supplies therapeutic apheresis devices and extracorporeal blood treatment systems for applications including plasma exchange, immunoadsorption, and renal care through the Fresenius Medical Care division. | Provides more effective treatment of autoimmune and renal diseases, greater accuracy in procedures, and minimized complexity, as well as facilitates patient monitoring and overall procedure safety. |
|
|
Designs technologies for automated blood and plasma collection for the use in donor apheresis and blood management in blood centers and hospitals around the world. | Enables higher efficiency, greater donor safety and convenience, reduces the need for manual interventions, and optimizes the management of blood components and operations. |
|
|
Manufactures membranes and therapeutic apheresis solutions for the selective removal of blood components and the purification of plasma in the course of treating autoimmune, neurological, and liver diseases. | Allows more effective removal of certain blood components, enhances procedural effectiveness, reduces potential adverse effects, and facilitates plasma purification. |
|
|
Produces extracorporeal blood treatment solutions and therapeutic apheresis products integrated with infusion therapies and critical care solutions for hospitals and specialty clinics. | Increases the efficiency of treatment processes, ensures reliable blood processing and fluid management, and improves overall treatment results. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The apheresis market operates within a complex interconnected ecosystem, which includes product innovation, regulatory oversight, manufacturing, distribution, and end-user adoption across multiple care settings. At the core of the ecosystem are manufacturers, which include Terumo Corporation (Japan), Fresenius SE & Co. KGaA (Germany), and Haemonetics Corporation (US). They are supported by academic institutes, clinical research bodies, and technology partners. Surrounding this network are regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and national health authorities that enforce strict compliance with device safety, sterility, performance standards, and post-market surveillance. Downstream, the ecosystem culminates with diverse end users, including blood collection centers and blood component providers, hospitals & transfusion centers, and other end users whose clinical needs, workflow requirements, and safety priorities directly shape product selection, adoption rates, and long-term technology evolution within the market.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
By type, the apheresis market is classified into donor apheresis and therapeutic apheresis. Of these, the donor apheresis segment is expected to exhibit the highest CAGR over the forecast period, driven by rising global demand for plasma and blood derivatives, increasing awareness of voluntary blood donations, and the growing need for source plasma to produce plasma-derived products. Furthermore, innovation in automated donor apheresis equipment has improved collection efficiency, reduced processing time, and enhanced donor safety and convenience, leading to increased adoption by blood banks and plasma centers.
In 2025, plasmapheresis dominated the apheresis market, driven by the increasing number of patients suffering from autoimmune diseases, neurologic diseases, hematologic and renal disorders, which require the application of plasma exchange procedures. Moreover, advanced technologies in plasmapheresis procedures, such as automated plasma separation, efficient plasma collection, rapid procedures, and donor safety, are further fueling the demand for apheresis.
In 2025, the centrifugation segment dominated the global apheresis market. The growing popularity of the centrifugation technique, driven by high efficiency in separating blood components, is expected to contribute significantly towards the growth of the apheresis segment. The growth of this segment is further supported by its ability to process large blood volumes with high precision and flexibility, making it highly preferred in blood banks, hospitals, and plasma collection centers.
REGION
Asia Pacific to be the fastest-growing region in global apheresis during the forecast period
The Asia Pacific is emerging as one of the most dynamic regions in the global apheresis market and is expected to witness the fastest growth rate over the coming years. This momentum is being driven by a combination of structural and behavioral shifts across the region. Healthcare systems in many APAC countries are evolving, with governments and private players investing heavily in infrastructure, advanced medical technologies, and specialized treatment capabilities. Emerging economies such as China and India are not only investing in healthcare modernization but are also seeing a growing patient pool and increasing demand for advanced therapies that rely on apheresis. Together, these factors are creating a strong foundation for sustained market expansion.
APHERESIS MARKET: COMPANY EVALUATION MATRIX
In the apheresis market matrix, Terumo Corporation (Star) leads with a strong market share and extensive product footprint, driven by its advanced equipment and technologies. Kaneka Corporation (Emerging Leader) is gaining visibility with its specialized blood purification and adsorption-based therapeutic apheresis solutions, strengthening its position through innovation and niche clinical applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Terumo Corporation (Japan)
- Fresenius SE & Co. KGaA (Germany)
- Fresenius Medical Care AG (Germany)
- Haemonetics Corporation (US)
- B. Braun SE (Germany)
- Becton, Dickinson and Company (US)
- ASAHI KASEI MEDICAL CO., LTD. (Japan)
- Otsuka Holdings Co., Ltd (Japan)
- medica spa (Italy)
- Sumitomo Bakelite Co., Ltd. (Japan)
- KANEKA CORPORATION (Japan)
- Vantive (US)
- Miltenyi Biotech (Germany)
- Nikkiso Co., Ltd. (Japan)
- Toray Industries, Inc. (Japan)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 2.81 Billion |
| Market Forecast in 2026 (Value) | USD 3.02 Billion |
| Market Forecast in 2031 (Value) | USD 4.41 Billion |
| Growth Rate | CAGR of 7.9% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Million/Billion), Volume (Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, South America, Middle East & Africa |
WHAT IS IN IT FOR YOU: APHERESIS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | In-depth assessment of apheresis by product (disposable, reusable), type (donor apheresis, therapeutic apheresis), procedure (plasmapheresis, plateletpheresis, leukapheresis, erythrocytapheresis, other procedures), technology (centrifugation, membrane separation), along with evaluation of automation capabilities, donor/patient safety features, and procedure efficiency |
|
| Company Information | Comprehensive profiles of leading global players such as Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, Asahi Kasei Medical Co., Ltd., B. Braun SE, Kaneka Corporation, and other Partners |
|
| Geographic Analysis | Region- and country-level demand mapping across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa; evaluation of regulatory frameworks, biologics adoption, pricing dynamics, and healthcare infrastructure |
|
RECENT DEVELOPMENTS
- October 2025 : Miltenyi Biotec and MiLaboratories collaborated to enhance the development of next-generation cell and gene therapies through a synergistic combination of bioinformatics, immune-profiling, and analytics software technologies, along with cell processing and therapy technologies of Miltenyi Biotec.
- December 2024 : In partnership with Ori Biotech, Fresenius Kabi has made progress on providing scalable manufacturing capabilities for cell and gene therapy via automation and manufacturing technology.
- November 2023 : Japan Medical Device Technology Co., Ltd. was acquired by Kaneka Corporation as part of a move towards strengthening its business operations within the area of medical devices in order to grow its Healthcare Solutions Unit.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.2
RESTRAINTS
4.2.3
OPPORTUNITIES
4.2.4
CHALLENGES
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMICS INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
5.2.4
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2023-2025)
5.6.2
AVERAGE SELLING PRICE TREND, BY REGION (2023-2025)
5.7
TRADE ANALYSIS
5.7.1
IMPORT SCENARIO (HS CODE 901890)
5.7.2
EXPORT SCENARIO (HS CODE 901890)
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.11
SUCCESS STORIES AND REAL-WORLD APPLICATIONS
5.12
IMPACT OF 2025 US TARIFF – APHERESIS MARKET
5.12.1
INTRODUCTION
5.12.2
KEY TARIFF RATES
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES
5.12.4.1
US
5.12.4.2
EUROPE
5.12.4.3
APAC
5.12.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN APHERESIS SYSTEMS
6.1.2
DEVELOPMENT OF CLOSED-LOOP AUTOMATED CELL THERAPY MANUFACTURING PLATFORMS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
USE OF REAL-TIME BIOSENSORS AND DIGITAL MONITORING IN APHERESIS PROCEDURES
6.2.2
INCREASING USE OF RFID AND TRACEABILITY TECHNOLOGIES IN BLOOD MANAGEMENT
6.3
ADJACENT TECHNOLOGIES
6.3.1
EXPANSION OF CELL AND GENE THERAPY MANUFACTURING TECHNOLOGIES
6.3.2
EXPANSION OF THERAPEUTIC FILTRATION AND ADSORPTION TECHNOLOGIES
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.5
PATENT ANALYSIS
6.6
FUTURE APPLICATIONS
6.7
IMPACT OF AI/GEN AI ON APHERESIS MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN THE APHERESIS MARKET
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN THE APHERESIS MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN APHERESIS MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
RECYCLED AND ECO-FRIENDLY MATERIALS FOR APHERESIS
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5
MARKET PROFITABILITY
9
APHERESIS MARKET, BY PRODUCTS (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
COMPARATIVE ASSESSMENT OF KEY APHERESIS PRODUCTS, THEIR MARKET POTENTIAL, AND DEMAND PATTERNS BY VARIOUS SUPPLIER COMPANIES
9.1
INTRODUCTION
9.2
APHERESIS DEVICES
9.3
APHERESIS DISPOSABLES
10
APHERESIS MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
TYPE-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING APHERESIS EQUIPMENT ADOPTION IN DIVERSE INDUSTRIES
10.1
INTRODUCTION
10.2
DONOR APHERESIS
10.3
THERAPEUTIC APHERESIS
10.3.1
NEUROLOGICAL DISORDERS
10.3.2
BLOOD DISORDERS
10.3.3
RENAL DISORDERS
10.3.4
AUTOIMMUNE DISORDERS
10.3.5
METABOLIC DISORDERS
10.3.6
CARDIOVASCULAR DISORDERS
10.3.7
OTHER DISORDERS
NOTE: OTHERS INCLUDE ONCOLOGY AND CELLULAR THERAPY APPLICATIONS, DERMATOLOGICAL DISORDERS, TRANSPLANTATION-RELATED APPLICATIONS, INFECTIOUS DISEASES, GASTROINTESTINAL DISORDERS, HYPERVISCOSITY SYNDROME, AND OTHER RARE THERAPEUTIC INDICATIONS.
11
APHERESIS MARKET, BY PROCEDURE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
PROCEDURE-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING APHERESIS EQUIPMENT ADOPTION IN DIVERSE INDUSTRIES
11.1
INTRODUCTION
11.2
PLASMAPHERESIS
11.2
PLATELETPHERESIS
11.2
ERYTHROCYTAPHERESIS
11.2
LEUKAPHERESIS
11.3
PHOTOPHERESIS
11.3
OTHER PROCEDURES
NOTE: OTHER PROCEDURES INCLUDE HEMOADSORPTION, IMMUNOADSORPTION, AND LIPID APHERESIS.
12
APHERESIS MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
TECHNOLOGY-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING APHERESIS EQUIPMENT ADOPTION IN DIVERSE INDUSTRIES
12.1
INTRODUCTION
12.2
CENTRIFUGATION
12.2.1
CONTINUOUS FLOW CENTRIFUGATION
12.2.2
INTERMITTENT FLOW CENTRIFUGATION
12.3
MEMBRANE SEPARATION
13
APHERESIS MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
SECTOR-SPECIFIC ADOPTION DRIVERS, DEMAND DYNAMICS, AND MARKET POTENTIAL ACROSS EACH END-USE INDUSTRY
14.1
INTRODUCTION
14.2
BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
14.3
HOSPITALS & TRANSFUSION CENTERS
14.4
OTHER END USERS
NOTE: OTHER END USERS INCLUDE EMERGENCY MEDICAL SERVICE PROVIDERS, ACUTE CARE CENTERS, AND MEDICAL & ACADEMIC INSTITUTES.
14
APHERESIS MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
ASSESSING GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY GEOGRAPHIES AND COUNTRIES
15.1
INTRODUCTION
15.2
NORTH AMERICA
15.2.1
NORTH AMERICA VOLUME ANALYSIS – 2024 – 2031 (THOUSAND UNITS)
15.2.2
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.3
US
15.2.4
CANADA
15.3
EUROPE
15.3.1
EUROPE VOLUME ANALYSIS – 2024 – 2031 (THOUSAND UNITS)
15.3.2
MACROECONOMIC OUTLOOK FOR EUROPE
15.3.3
GERMANY
15.3.4
UK
15.3.5
FRANCE
15.3.6
ITALY
15.3.7
SPAIN
15.3.9
SWITZERLAND
15.3.10
NETHERLANDS
15.3.11
REST OF EUROPE
15.4
ASIA PACIFIC
15.4.1
ASIA PACIFIC VOLUME ANALYSIS – 2024 – 2031 (THOUSAND UNITS)
15.4.2
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.3
JAPAN
15.4.4
CHINA
15.4.5
INDIA
15.4.6
AUSTRALIA
15.4.7
SOUTH KOREA
15.4.8
THAILAND
15.4.9
SINGAPORE
15.4.10
REST OF ASIA PACIFIC
15.5
LATIN AMERICA
15.5.1
LATIN AMERICA VOLUME ANALYSIS – 2024 – 2031 (THOUSAND UNITS)
15.5.2
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.3
BRAZIL
15.5.4
MEXICO
15.5.5
REST OF LATIN AMERICA
15.6
MIDDLE EAST & AFRICA
15.6.1
MIDDLE EAST & AFRICA VOLUME ANALYSIS – 2024 – 2031 (THOUSAND UNITS)
15.6.2
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.3
GCC COUNTRIES
15.6.3.1
KINGDOM OF SAUDI ARABIA (KSA)
15.6.3.2
UNITED ARAB EMIRATES (UAE)
15.6.3.3
OTHER GCC COUNTRIES
15.6.4
REST OF MIDDLE EAST & AFRICA
NOTE: REST OF EUROPE INCLUDES SWEDEN, PORTUGAL, POLAND, FINLAND, DENMARK, AUSTRIA, ICELAND, AND IRELAND.
NOTE: REST OF ASIA PACIFIC INCLUDES BANGLADESH, BHUTAN, NEPAL, SRI LANKA, PHILIPPINES, SINGAPORE, VIETNAM, TAIWAN, CAMBODIA, AND INDONESIA
NOTE: THE REST OF LATIN AMERICA INCLUDES ECUADOR, PERU, URUGUAY, CUBA, AND CHILE
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and key players' strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the apheresis market. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the apheresis market. The primary sources from the demand side include medical OEMs, medical device ISOs, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights into key industry trends & key market dynamics.
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global apheresis market size was determined using revenue share analysis of leading players. For this purpose, key market players were identified, and their revenues from the apheresis business were determined using insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and marketing executives.
To calculate the global market value, segmental revenues were derived from the revenue mapping of major solution/service providers. This process involves the following steps:
- Generating a list of major global players operating in the apheresis market
- Mapping annual revenues generated by major global players from the apheresis segment (or nearest reported business unit/service category)
- Revenue mapping of key players to cover a major share of the global market as of 2025
- Extrapolating the global value of the apheresis industry
Data Triangulation
After arriving at the overall market size through the market size estimation process explained above, the global apheresis market was segmented and subsegmented. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the apheresis market was validated using both top-down and bottom-up approaches.
Market Definition
Apheresis is a medical technology and extracorporeal blood separation procedure in which whole blood is withdrawn from a donor or patient and processed through a device that separates specific blood components. The desired component is collected or treated, while the remaining blood components are returned to the individual. The process primarily uses centrifugation or membrane filtration to separate blood components.
Apheresis encompasses both donor and therapeutic procedures and is widely used in transfusion medicine, hematology, oncology, nephrology, neurology, and immunology for blood component collection and the treatment of various disorders, including autoimmune diseases, hematologic conditions, and metabolic disorders.
Key Stakeholders
- Companies manufacturing apheresis devices & disposables
- Original equipment manufacturing companies
- Suppliers and distributors of apheresis devices & disposables
- Healthcare service providers
- Health insurance payers
- Government bodies/municipal corporations
- Regulatory bodies
- Medical research institutes
- Business research and consulting service providers
- Venture capitalists
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the global apheresis devices market based on product, type, procedure, technology, end user, and region
-
To provide detailed information regarding the major factors influencing the market growth
(such as drivers, restraints, opportunities, and challenges) along with the current trends - To strategically analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the overall apheresis market
- To analyze the opportunities in the global apheresis market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, expansions, strategic alliances, and acquisitions in the global apheresis market.
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global apheresis market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top twelve companies
Company Information
- Detailed analysis and profiling of additional market players (up to 10)
Geographic Analysis
- Further breakdown of the Rest of Europe's apheresis market into Russia, Finland, Switzerland, Turkey, the Czech Republic, the Netherlands, Norway, Poland, Portugal, Romania, Estonia, Austria, and Belgium
- Further breakdown of the Rest of Asia Pacific’s apheresis market into Taiwan, New Zealand, and Sri Lanka
- Further breakdown of the Rest of Latin America’s apheresis market into Uruguay, Costa Rica, Bolivia, Venezuela, and Paraguay
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Apheresis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
